Analyst Price Target is $6.10
▲ +60.10% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Geron in the last 3 months. The average price target is $6.10, with a high forecast of $10.00 and a low forecast of $4.50. The average price target represents a 60.10% upside from the last price of $3.81.
Current Consensus is
Moderate Buy
The current consensus among 5 investment analysts is to moderate buy stock in Geron. This Moderate Buy consensus rating has held steady for over two years.
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Read More